EPharmaSolutions And CenterWatch Partner To Improve Patient Eligibility And Access To Clinical Trials

CONSHOHOCKEN, Pa., March 21, 2013 /PRNewswire/ -- ePharmaSolutions, a leading clinical services and eClinical solutions provider, and CenterWatch, a top provider of clinical research business information and the leading online publisher of active clinical trial listings for patients and the public, are partnering to provide sponsors and patients with a novel solution that will increase the opportunities for patients to find trials for which they may qualify.

Only 5% of patients who respond to a specific patient recruitment advertisement ever end up participating, for one reason or another.   This is very discouraging for those patients who are highly motivated to gain access to experimental treatments through clinical trials.    Until now, 95% of patients who responded to a recruitment advertisement but were ineligible to participate are ever introduced to other studies for which they might qualify. ePharmaSolutions and CenterWatch, along with a consortium of the largest pharmaceutical companies and contract research organizations in the world, are aiming to change that through a collaborative effort called the 'Referral Plus' Initiative.  

The Referral Plus Initiative uses a proprietary technology platform developed by ePharmaSolutions that programmatically matches patients who screen and disqualify from one trial into other "like" studies using a geo-therapeutic matching algorithm that links the patients' screening responses to entry criteria of the studies listed on the platform in real time.   Patients who are not matched to active studies are invited to register with PatientLive™, a Microsoft based application that provides patients with personalized information about approved medications, new medical therapies and new clinical trial opportunities for their condition(s) provided by CenterWatch and hosted in Microsoft HealthVault. 

For pharmaceutical companies, Referral Plus helps optimize the millions of dollars spent on patient recruitment advertising while providing patients who respond to those advertisements with better chances to find studies for which they may qualify.

1 2 Next › Last »